File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immune-epigenetic crosstalk in haematological malignancies

TitleImmune-epigenetic crosstalk in haematological malignancies
Authors
Keywordscancer
epigenetics
leukemia
niche
stem cell
Issue Date21-Sep-2023
PublisherFrontiers Media
Citation
Frontiers in Cell and Developmental Biology, 2023, v. 11 How to Cite?
Abstract

Haematological malignancies comprise a diverse set of lymphoid and myeloid neoplasms which can arise during any stage of haematopoiesis in the bone marrow. Accumulating evidence suggests that chronic inflammation generated by inflammatory cytokines secreted by tumour and the tumour-associated cells within the bone marrow microenvironment initiates signalling pathways in malignant cells, resulting in activation of master transcription factors including Smads, STAT3, and NF-κB which confer cancer stem cell phenotypes and drive disease progression. Deciphering the molecular mechanisms for how immune cells interact with malignant cells to induce such epigenetic modifications, specifically DNA methylation, histone modification, expression of miRNAs and lnRNAs to perturbate haematopoiesis could provide new avenues for developing novel targeted therapies for haematological malignancies. Here, the complex positive and negative feedback loops involved in inflammatory cytokine-induced cancer stem cell generation and drug resistance are reviewed to highlight the clinical importance of immune-epigenetic crosstalk in haematological malignancies.


Persistent Identifierhttp://hdl.handle.net/10722/337917
ISSN
2023 Impact Factor: 4.6
2023 SCImago Journal Rankings: 1.576
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Hera-
dc.contributor.authorSugimura, Ryohichi-
dc.date.accessioned2024-03-11T10:24:54Z-
dc.date.available2024-03-11T10:24:54Z-
dc.date.issued2023-09-21-
dc.identifier.citationFrontiers in Cell and Developmental Biology, 2023, v. 11-
dc.identifier.issn2296-634X-
dc.identifier.urihttp://hdl.handle.net/10722/337917-
dc.description.abstract<p>Haematological malignancies comprise a diverse set of lymphoid and myeloid neoplasms which can arise during any stage of haematopoiesis in the bone marrow. Accumulating evidence suggests that chronic inflammation generated by inflammatory cytokines secreted by tumour and the tumour-associated cells within the bone marrow microenvironment initiates signalling pathways in malignant cells, resulting in activation of master transcription factors including Smads, STAT3, and NF-κB which confer cancer stem cell phenotypes and drive disease progression. Deciphering the molecular mechanisms for how immune cells interact with malignant cells to induce such epigenetic modifications, specifically DNA methylation, histone modification, expression of miRNAs and lnRNAs to perturbate haematopoiesis could provide new avenues for developing novel targeted therapies for haematological malignancies. Here, the complex positive and negative feedback loops involved in inflammatory cytokine-induced cancer stem cell generation and drug resistance are reviewed to highlight the clinical importance of immune-epigenetic crosstalk in haematological malignancies.<br></p>-
dc.languageeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Cell and Developmental Biology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcancer-
dc.subjectepigenetics-
dc.subjectleukemia-
dc.subjectniche-
dc.subjectstem cell-
dc.titleImmune-epigenetic crosstalk in haematological malignancies-
dc.typeArticle-
dc.identifier.doi10.3389/fcell.2023.1233383-
dc.identifier.scopuseid_2-s2.0-85173926149-
dc.identifier.volume11-
dc.identifier.eissn2296-634X-
dc.identifier.isiWOS:001078169000001-
dc.identifier.issnl2296-634X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats